The European Commission (EC) has granted Merck, Sharp & Dohme (MSD; NYSE: MRK) approval for a pediatric indication for its vaccine Ervebo, expanding its use as an active immunization for individuals aged 1 year or older against Ebola virus disease (EVD) caused by Zaire ebolavirus. This life-threatening condition has been a significant global health concern, and the vaccine’s approval marks a step forward in broadening protection against the disease.
Expanding Ervebo’s Reach to Younger Populations
Previously, Ervebo was approved for individuals above 18 years of age. The new approval allows for the vaccination of a younger demographic, potentially saving more lives by preventing the spread of the deadly virus. This expansion in the age range is crucial in the ongoing efforts to control and prevent Ebola outbreaks.
MSD’s Commitment to Global Health and Vaccine Stockpile
Merck has demonstrated its commitment to global health by delivering over 500,000 doses of Ervebo to the International Coordinating Group (ICG) on Vaccine Provision. This followed an agreement entered into in 2021 to establish the first global Ebola vaccine stockpile. The stockpile is a critical component in the global response to Ebola, ensuring rapid access to vaccines during outbreaks and supporting preparedness efforts worldwide.-Fineline Info & Tech
